QIBA PET-Amyloid Biomarker Committee (BC) Call
Friday, July 12, 2019 at 9 AM CT
Call Summary

In attendance:		**RSNA**
Dawn Matthews, MS (Co-chair)	*Satoshi Minoshima, MD, PhD (Co-chair)*	Joe Koudelik
Anne Smith, PhD (Co-chair)	Nancy Obuchowski, PhD	Susan Stanfa

Moderator: Dr. Smith

Status on PET-Amyloid Profile

- Significant overlap was noted between the ADNI and FDG-PET imaging protocols; details extracted to develop the PET-Amyloid site "feasibility" questionnaire
- The QIBA FDG-PET BC's , Stage 3: Technically Confirmed Profile can be located on the QIBA Wiki Profiles page; the PET-Amyloid BC can benefit from this work
- Three tasks not already addressed by other Profiles were identified: subject motion, subject positioning and transaxial uniformity; the PET-Amyloid BC to focus on them in their Profile
- The Amyloid Profile is currently in Stage 2: Consensus, and is progressing toward Stage 3: Technically Confirmed
    - To reach Stage 3, the conformance process must be finalized through feasibility-testing
    - Ms. Matthews consulted with Mr. O'Donnell regarding the questionnaire format strategy used by the FDG-PET BC
    - A checklist with actor-specific tasks (action items) was recommended as a best practice

- Discussion regarding whether the PET-Amyloid BC intends to advance to Stage 4: Claim Confirmed
    - The tremendous value in attaining Stage 3: Technically-Confirmed for any Profile was noted; consensus was to declare victory upon Stage 3 completion and render the PET-Amyloid BC dormant
    - Upon the PET-Amyloid BC meeting this goal, it may be considered for dormant status, per the Committee Sunset Process on the QIBA Wiki
    - The completed PET-Amyloid Profile to be made available both to U.S. and international users

Next Steps

- Sites to be consulted regarding subject motion, subject positioning and transaxial uniformity
    - Ms. Matthews to contact Drs. Subramaniam and Wahl
- Actor-specific checklists to be distributed to participating sites
- Dr. Smith (with a cc to Dr. Minoshima and Ms. Matthews), to request a DRO update from Dr. Kinahan
- Once completed, the PET-Amyloid Profile to be promoted as a finished product
    - iCROs and Pharma to be made aware of this valuable resource, and volunteer contributors to be acknowledged for their generous efforts over the past four years

***QIBA Nuclear Medicine Schedule**:*

The next scheduled QIBA calls will be as follows at **9 am CT** unless otherwise noted:

7/26	NM Leadership – TBD
8/2	FDG-PET BC
8/13	SPECT BC: TC^{99m} @ 2pm CT
8/9	PET Amyloid BC
8/16	I-123 BC - TBD by co-chairs
8/23	NM Coordinating Committee @ 9 am CT